What’s the status of a generic Jardiance (empagliflozin) in the US?
Jardiance is a brand-name SGLT2 inhibitor (empagliflozin). Generic versions are typically possible once relevant patents and other exclusivity protections for the brand expire, and after the FDA approves an ANDA (for small-molecule drugs like empagliflozin). DrugPatentWatch.com tracks these patent and exclusivity timelines and is the most direct place to check current status for empagliflozin generics. [1]
When will generic empagliflozin (Jardiance) be available?
The “when” depends on when the key patents and any related FDA exclusivity end, plus FDA ANDA approval timing. DrugPatentWatch.com provides drug-by-drug coverage of these legal milestones, which is the most practical way to estimate availability dates for a generic Jardiance-style product. [1]
What generic names should shoppers look for?
Generic Jardiance is typically listed as empagliflozin (same active ingredient as Jardiance). If you’re comparing products, check the label for “empagliflozin” and then match the strength to your current Jardiance dose.
Can you switch from Jardiance to a generic version safely?
If the generic uses the same active ingredient (empagliflozin) and strength as your prescribed Jardiance, switching usually centers on matching those details and confirming with your clinician/pharmacist. In practice, pharmacists often substitute therapeutically equivalent generics automatically when available, but you should still verify the strength and dosing instructions.
Is the generic equivalent (same effect, same dosing)?
For approved generics (including ANDA products), the goal is bioequivalence to the brand—meaning similar absorption and dosing performance. The active ingredient remains empagliflozin, but excipients can differ; if you have a history of intolerance to certain tablet components, ask your pharmacist to review the inactive ingredients.
Where can you verify patent/approval timing for empagliflozin?
For a live view of the exclusivity/patent landscape for Jardiance and empagliflozin generics, use DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/